B-cell chronic lymphocytic leukemia is a heterogeneous disease with a variety of somatic mutations found in patients, NOTCH1 and SF3B1 mutations being among the most frequent. They predict an adverse disease course and no targeted therapy for them exist. This project aims to perform CRISPR/Cas9 screen to reveal unique susceptibilities of NOTCH1 or SF3B1 mutated cells that might lead to the identification of novel therapeutical targets. These will be validated and molecular mechanisms proposed.

Publikace